These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 29862440)

  • 1. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
    Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
    BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing laboratory costs of smear/culture and Xpert
    Naidoo P; Dunbar R; du Toit E; van Niekerk M; Squire SB; Beyers N; Madan J
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1377-1385. PubMed ID: 27725051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.
    Lawn SD; Brooks SV; Kranzer K; Nicol MP; Whitelaw A; Vogt M; Bekker LG; Wood R
    PLoS Med; 2011 Jul; 8(7):e1001067. PubMed ID: 21818180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the Xpert MTB/RIF assay in the diagnosis of tuberculosis in formalin-fixed, paraffin-embedded tissues.
    Polepole P; Kabwe M; Kasonde M; Tembo J; Shibemba A; O'Grady J; Kapata N; Zumla A; Bates M
    Int J Mycobacteriol; 2017; 6(1):87-93. PubMed ID: 28317811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia.
    Lorent N; Kong C; Kim T; Sam S; Thai S; Colebunders R; Rigouts L; Lynen L
    Int J Tuberc Lung Dis; 2015 Dec; 19(12):1528-35. PubMed ID: 26614197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Cepheid ® Xpert MTB/RIF ® and TB-Biochip ® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis.
    Kurbatova EV; Kaminski DA; Erokhin VV; Volchenkov GV; Andreevskaya SN; Chernousova LN; Demikhova OV; Ershova JV; Kaunetis NV; Kuznetsova TA; Larionova EE; Smirnova TG; Somova TR; Vasilieva IA; Vorobieva AV; Zolkina SS; Cegielski JP
    Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):735-43. PubMed ID: 23263819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.
    Cox HS; Mbhele S; Mohess N; Whitelaw A; Muller O; Zemanay W; Little F; Azevedo V; Simpson J; Boehme CC; Nicol MP
    PLoS Med; 2014 Nov; 11(11):e1001760. PubMed ID: 25423041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial.
    Agizew T; Chihota V; Nyirenda S; Tedla Z; Auld AF; Mathebula U; Mathoma A; Boyd R; Date A; Pals SL; Lekone P; Finlay A
    BMC Infect Dis; 2019 Dec; 19(1):1058. PubMed ID: 31842773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving rifampicin-resistant tuberculosis diagnosis using Xpert
    Dunbar R; Naidoo P; Beyers N; Langley I
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):890-898. PubMed ID: 29991398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.
    Andrews JR; Lawn SD; Rusu C; Wood R; Noubary F; Bender MA; Horsburgh CR; Losina E; Freedberg KA; Walensky RP
    AIDS; 2012 May; 26(8):987-95. PubMed ID: 22333751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.
    Menzies NA; Cohen T; Lin HH; Murray M; Salomon JA
    PLoS Med; 2012; 9(11):e1001347. PubMed ID: 23185139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating TB diagnostic costs incurred under the National Tuberculosis Elimination Programme: a costing study from Tamil Nadu, South India.
    Muniyandi M; Lavanya J; Karikalan N; Saravanan B; Senthil S; Selvaraju S; Mondal R
    Int Health; 2021 Dec; 13(6):536-544. PubMed ID: 33570132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug Resistant Mycobacterium tuberculosis Among Military and Civilian Personnel seen at a Tertiary Military Hospital, Manila, Philippines (2015-2018).
    Velasco JM; Gaurano N; Valderama MT; Nogrado K; Diones PC; Lopez MN; Liao C; Chua D; Develos M; Fernandez S; Macareo L; Swierczewski B
    Mil Med; 2020 Aug; 185(7-8):e1106-e1111. PubMed ID: 31915831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.